ClinicalTrials.gg
CompletedNCT00367484Updated Feb 27, 2014Results posted

Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

A Phase 4 interventional study of Rebif® (clone 484-39) in Relapsing Remitting Multiple Sclerosis, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-02-27.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
460
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
4th of 21
460 · median 80
Started
2004
with 3 others
Phase 4
13 of 21
none open now
Registered
7th of 21
by date
Lead sponsor
5 of 21
Merck KGaA, Darmstadt, Germany

Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 4th largest by enrollment, is one of 4 that started in 2004, is one of 13 in phase 4, and was the 7th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The objectives of the study are:

  • comparison of the incidence and time course of the development of neutralizing antibodies (NAbs) to Rebif after 48 weeks of therapy, to historical data from Serono clinical trial databases to assess the safety and tolerability of Rebif®
03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have multiple sclerosis (MS) with two or more relapses in the past two years and is eligible for interferon therapy.
  • Be between 18 and 60 years of age, inclusive.
  • Have given written , prior to any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to their future medical care.
  • Be willing and able to follow all study procedures for the duration of the study.
  • Have an Expanded Disability Scale Score (EDSS) less than 6.0
  • If female, she must either

    1. be post menopausal or surgically sterilised; or
    2. use a hormonal , intra uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study; and
    3. be neither pregnant nor breast feeding. Confirmation that the subject is not pregnant must be established by a negative SERUM human Chorionic Gonadotrophin (hCG) pregnancy test between 28 to 7 days before Study Day 0.Urine pregnancy test must be done if serum hCG pregnancy test was performed more than 7 days before Study Day 0. A pregnancy test is not required if the subject is post menopausal or surgically sterilised.

Exclusion criteria

Exclusion Criteria:

  • Prior Interferon beta therapy (either beta-1b or beta-1a).
  • Major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol.
  • Significant therapy within the 6 months prior to enrolment.
  • Known history of to natural or recombinant interferon beta, human serum albumin, or any other component of the formulation.
  • Epilepsy with a history of seizures not adequately controlled by treatment.
  • Have greater than Grade 1 toxicity for liver function tests ( (AST), Alanine Transaminase (ALT), Gamma-Glutamyl Transferase (GGT) or total ) at the Screening visit
  • Have significant leukopenia (greater than Grade 1 toxicity for total white blood cell count or lymphopenia) at the Screening visit
  • Have had treatment with oral or systemic or Adrenocorticotrophic hormone (ACTH) within 1 month of the Screening visit or between the screening visit and study day 0.
  • Cytokine or anti-cytokine therapy within the 3 months prior to the Screening visit or between the screening visit and study day 0.
  • Use of immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide) within the 6 months prior to the Screening visit or between the screening visit and study day 0.
  • Have taken intravenous immunoglobulin or glatiramer acetate or mitoxantrone or any drug or experimental procedure within the 3 months prior to the Screening visit or between the screening visit and study day 0.
  • Prior use of cladribine or have received total lymphoid irradiation.
  • Presence of systemic disease that might interfere with patient safety, compliance or evaluation of the condition under study (e.g. poorly controlled insulin-dependent diabetes, Lyme disease, cardiac disease, (HIV), human T-lymphotrophic virus 1 (HTLV-1)).

Other concurrent systemic disorders incompatible with the study (at the Investigator's discretion).

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
460 participants (actual)

Study arms

  • Experimental
    Rebif® (clone 484-39)

    Rebif® 44 mcg, three times per week (tiw), subcutaneously (s.c.) During the first 4 weeks of the study, subjects underwent a dose titration regimen of 40% of Rebif® 22 mcg or 20% of Rebif® 44 mcg tiw (8.8 mcg per injection) in the first and second week followed by 100% of Rebif® 22 mcg or 50% of Rebif® 44 mcg (22 mcg per injection) in the third and fourth week. After 4 weeks, subjects received 44 mcg injected s.c. tiw.

    Biological: Rebif® (clone 484-39)

Interventions

  • s.c. administered Rebif®

    Also known as: Recombinant-human interferon beta-1a, r-hIFN Beta-1a

06

What researchers measure

Primary outcomes

  1. Number of Participants Testing Positive for Neutralising Antibody (NAb)

    Participants who were NAb+ at 48 weeks (or at the last available NAb assessment up to Week 48). The NAb+ value was defined as NAb ≥ 20 NU/ml.

    Time frame: 48 Weeks

07

Results

Posted Aug 27, 2010

Participant flow

Subjects were screened for enrollment from 27 May 2004 and attended the last visit on 30 January 2006. Four hundred and eighty four subjects were screened for enrollment and 460 were enrolled. Two subjects (0.4%) were excluded from the ITT Population since they had no post-Baseline NAb assessment due to withdrawing from the study prematurely.

Participant flow — Overall Study
MilestoneRebif® (Clone 484-39)
Started460
Completed443
Not completed17
Withdrew: Adverse event7
Withdrew: Withdrew informed consent5
Withdrew: Travel to usa1
Withdrew: Lost to follow-up1
Withdrew: Protocol violation1
Withdrew: The choice of the patient1
Withdrew: Lack of efficacy1

Outcome measures

PrimaryNumber of Participants Testing Positive for Neutralising Antibody (NAb)

Participants who were NAb+ at 48 weeks (or at the last available NAb assessment up to Week 48). The NAb+ value was defined as NAb ≥ 20 NU/ml.

Time frame:
48 Weeks
Reported as:
Number · NAb+ participants
Number of Participants Testing Positive for Neutralising Antibody (NAb)
NAb+ participantsRebif® (Clone 484-39)
Number of Participants Testing Positive for Neutralising Antibody (NAb)73

Adverse events

Collected over 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rebif® (Clone 484-39)—11/460 (2.4%)378/460 (82.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventRebif® (Clone 484-39)
PneumoniaInfections and infestations2/460
Herpes zosterInfections and infestations1/460
Injection site abscessInfections and infestations1/460
Injection site cellulitisInfections and infestations1/460
Urinary tract infectionInfections and infestations1/460
Ankle fractureInjury, poisoning and procedural complications1/460
FallInjury, poisoning and procedural complications1/460
Thermal burnInjury, poisoning and procedural complications1/460
Parathyroid tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/460
Renal cell carcinoma stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)1/460
Most frequent other events
Showing 10 of 17
Most frequent other events
EventRebif® (Clone 484-39)
Influenza like illnessGeneral disorders188/460
HeadacheNervous system disorders129/460
Injection site erythemaGeneral disorders67/460
PyrexiaGeneral disorders50/460
MyalgiaMusculoskeletal and connective tissue disorders43/460
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders40/460
FatigueGeneral disorders37/460
Upper respiratory tract infectionInfections and infestations37/460
Blood and lymphatic system disordersBlood and lymphatic system disorders36/460
ChillsGeneral disorders35/460

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rebif® (Clone 484-39)
<=18 years0
Between 18 and 65 years458
>=65 years0
Age, Continuous
Age, Continuous(years)Rebif® (Clone 484-39)
Mean36.0 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Rebif® (Clone 484-39)
Female336
Male122
Region of Enrollment
Region of Enrollment(participants)Rebif® (Clone 484-39)
Estonia36
France2
United Kingdom13
Hungary23
Lithuania69
Morocco5
Poland69
Romania87
Russian Federation43
Serbia80
Tunisia31
Neutralising Antibody (NAb) Status
Neutralising Antibody (NAb) Status(Participants not testing NAb positive)Rebif® (Clone 484-39)
Number458
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004, a primary completion of Jan 2006 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2006
First posted
Aug 23, 2006
Start
May 2004
Primary completionActual
Jan 2006
CompletionActual
Jan 2006
Results first posted
Aug 27, 2010
Last update
Feb 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00367484
Responsible party
Sponsor
First posted
Aug 23, 2006
Start date
May 2004
Primary completion
Jan 2006
Completion
Jan 2006
Results posted
Aug 27, 2010
Last update
Feb 27, 2014

Study contacts

Bettina Stubinski, M.D.
study director · Merck Serono SA - Geneva
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion